

Table 0.1. Exploratory Analysis Clinical Features

Clinical Characteristic	NHQS (n = 393)	HQS (n = 152)
Line of Therapy		
I	143 (36.76%)	48 (32.43%)
II	150 (38.56%)	64 (43.24%)
III	52 (13.36%)	23 (15.54%)
IV	22 (5.65%)	9 (6.08%)
V	12 (3.08%)	2 (1.35%)
VI	8 (2.05%)	1 (0.67%)
VII	1 (0.25%)	1 (0.67%)
VIII	1 (0.25%)	
Stage of Disease		
I	33 (9.06%)	14 (10%)
II	31 (8.51%)	10 (7.14%)
III	92 (25.27%)	34 (24.28%)
IV	208 (57.14%)	82 (58.57%)
Sex		
M	182 (46.78%)	65 (43.91%)
F	207 (53.21%)	83 (56.08%)
Smoking Status		
Never {0}	46 (11.82%)	23 (15.54%)
Former {1}	283 (72.75%)	104 (70.27%)
Current {2}	60 (15.42%)	21 (14.189%)
Age		
{20-29}	1 (0.25%)	
{30-39}	2 (0.51%)	
{40-49}	32 (8.24%)	14 (9.52%)
{50-59}	90 (23.19%)	34 (23.12%)
{60-69}	148 (38.14%)	53 (36.05%)
{70-79}	95 (24.48%)	41 (27.89%)
{80-89}	20 (5.15%)	5 (3.40%)
Tumor Type		
LC-NE	2 (1.35%)	9 (2.13%)
Squamous	32 (21.62%)	77 (19.79%)
Adeno	110 (74.32%)	286 (73.52%)
Other	4 (2.70%)	17 (4.37%)
PD-L1 Category		
PD-L1 + Chemotherapy	7 (1.79%)	7 (4.73%)
PD-L1 + CTLA4	65 (16.71%)	11 (7.43%)
PD-L1	317 (81.49%)	130 (87.83%)
Best Overall Survival Categorized		
SD	108 (28.64%)	39 (28.67%)
PD	127 (33.68%)	45 (33.08%)
CR/PR	142 (37.66%)	52 (38.23%)